Company news
Atrium Therapeutics, Inc. news in 2022
Atrium Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Avidity Biosciences, Inc. Announces Pricing of Upsized Public Offering of Common Stock
December 14, 2022
Avidity Announces Positive AOC 1001 Phase 1/2 MARINA™ Data Demonstrating First-Ever Successful Targeted Delivery of RNA to Muscle - Revolutionary Advancement for the Field of RNA Therapeutics
December 13, 2022
Avidity Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights
November 7, 2022
Avidity Biosciences Announces Phase 1/2 EXPLORE44™ Trial of AOC 1044 for Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping
October 10, 2022
Avidity Biosciences Announces Upcoming Presentations at 27th International Hybrid Annual Congress of World Muscle Society
October 5, 2022
Avidity Biosciences Announces the Phase 1/2 FORTITUDE™ Trial of AOC 1020 in Adults with Facioscapulohumeral Muscular Dystrophy
September 28, 2022
Avidity Biosciences Announces FDA Partial Clinical Hold on New Participant Enrollment in Phase 1/2 MARINA™ Trial
September 26, 2022
Avidity Biosciences Engages with Patient Communities During National Muscular Dystrophy Awareness Month as part of Commitment to Developing Muscular Dystrophy Programs
September 6, 2022
Avidity Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights
August 8, 2022
Avidity Biosciences Enrolls Patients in the MARINA™ Open-Label Extension Study
August 1, 2022
Avidity Biosciences Supports World Facioscapulohumeral Muscular Dystrophy (FSHD) Day and Presents Preclinical Data from FSHD Program
June 16, 2022
Avidity Biosciences Announces Upcoming Presentations at the 29th Annual FSHD Society International Research Congress
June 8, 2022
Avidity Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights
May 9, 2022
Avidity Biosciences Expands Role of Michael MacLean to Chief Financial and Chief Business Officer
April 4, 2022
Avidity Biosciences Announces Upcoming Presentations at the American Academy of Neurology 2022 Annual Meeting
March 28, 2022
Avidity Biosciences Announces Upcoming Presentations at the 2022 MDA Clinical & Scientific Conference
March 6, 2022
Avidity Biosciences Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Highlights
February 28, 2022
Avidity Biosciences Appoints Steve Hughes, M.D., as Chief Medical Officer
February 22, 2022